The Role of PGP9.5 As a Tumor Suppressor Gene in Human Cancer

Overview

Journal Int J Cancer

Specialty Oncology

Date 2008 May 31

PMID 18512240

Citations 33

Authors

Yutaka Tokumaru

Keishi Yamashita

Myoung Sook Kim

Hannah L Park

Motonobu Osada

Masaki Mori

David Sidransky

Affiliations

Soon will be listed here.

Abstract

PGP9.5 is a controversial molecule from an oncologic point of view. We recently identified frequent methylation of PGP9.5 gene exclusively in primary head and neck squamous cell carcinoma (HNSCC), suggesting that it could be a tumor suppressor gene. On the other hand, PGP9.5 was reported to be overexpressed in a subset of human cancers presumably due to intrinsic oncogenic properties or as a result of transformation. To demonstrate that PGP9.5 possesses tumor suppressive activity, we examined forced expression by stable transfection of PGP9.5 in 4 HNSCC cell lines. Although all 4 cell lines demonstrated reduced log growth rates in culture after transfection, only 2 cell lines with wild type p53 (011, 022) demonstrated decreased growth in soft agar. In 2 cell lines with mutant p53 (013, 019), we observed no altered growth in soft agar and increased sensitivity to UV irradiation. We then tested for and found a high frequency of promoter methylation in a larger panel of primary tumors including HNSCC, esophageal SCC, gastric, lung, prostate and hepatocellular carcinoma. Our data support the notion that PGP9.5 is a tumor suppressor gene that is inactivated by promoter methylation or gene deletion in several types of human cancers.

Citing Articles

Targeted epigenetic silencing of UCHL1 expression suppresses collagen-1 production in human lung epithelial cells.

Wu D, Lau A, Xu Y, Reinders-Luinge M, Koncz M, Kiss A Epigenetics. 2023; 18(1):2175522.

PMID: 38016026 PMC: 9980648. DOI: 10.1080/15592294.2023.2175522.

Ubiquitin C‑terminal hydrolase‑L1: A new cancer marker and therapeutic target with dual effects (Review).

Wang X, Zhang N, Li M, Hong T, Meng W, Ouyang T Oncol Lett. 2023; 25(3):123.

PMID: 36844618 PMC: 9950345. DOI: 10.3892/ol.2023.13709.

Research Progress for Targeting Deubiquitinases in Gastric Cancers.

An T, Lu Y, Gong Z, Wang Y, Su C, Tang G Cancers (Basel). 2022; 14(23).

PMID: 36497313 PMC: 9735992. DOI: 10.3390/cancers14235831.

Five tumor-associated autoantibodies expression levels in serum predict lung cancer and associate with poor outcome.

Li S, Ma Y, Xiong Y, Zhang P, Wang X, Wang Y Transl Cancer Res. 2022; 8(4):1364-1373.

PMID: 35116879 PMC: 8798311. DOI: 10.21037/tcr.2019.07.25.

Ubiquitin Carboxyl-Terminal Hydrolases and Human Malignancies: The Novel Prognostic and Therapeutic Implications for Head and Neck Cancer.

Rong C, Zhou R, Wan S, Su D, Wang S, Hess J Front Oncol. 2021; 10:592501.

PMID: 33585209 PMC: 7878561. DOI: 10.3389/fonc.2020.592501.

References

Hibi K, Liu Q, Beaudry G, Madden S, Westra W, Wehage S . Serial analysis of gene expression in non-small cell lung cancer. Cancer Res. 1998; 58(24):5690-4. View

Otsuki T, Yata K, Takata-Tomokuni A, Hyodoh F, Miura Y, Sakaguchi H . Expression of protein gene product 9.5 (PGP9.5)/ubiquitin-C-terminal hydrolase 1 (UCHL-1) in human myeloma cells. Br J Haematol. 2004; 127(3):292-8. DOI: 10.1111/j.1365-2141.2004.05205.x. View

Harada T, Harada C, Wang Y, Osaka H, Amanai K, Tanaka K . Role of ubiquitin carboxy terminal hydrolase-L1 in neural cell apoptosis induced by ischemic retinal injury in vivo. Am J Pathol. 2003; 164(1):59-64. PMC: 1602242. DOI: 10.1016/S0002-9440(10)63096-9. View

Takase T, Hibi K, Yamazaki T, Nakayama H, Taguchi M, Kasai Y . PGP9.5 overexpression in esophageal squamous cell carcinoma. Hepatogastroenterology. 2003; 50(53):1278-80. View

Yamashita K, Upadhyay S, Osada M, Hoque M, Xiao Y, Mori M . Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell. 2002; 2(6):485-95. DOI: 10.1016/s1535-6108(02)00215-5. View

Yamazaki T, Hibi K, Takase T, Tezel E, Nakayama H, Kasai Y . PGP9.5 as a marker for invasive colorectal cancer. Clin Cancer Res. 2002; 8(1):192-5. View

Nakanishi K, Sakamoto M, Yasuda J, Takamura M, Fujita N, Tsuruo T . Critical involvement of the phosphatidylinositol 3-kinase/Akt pathway in anchorage-independent growth and hematogeneous intrahepatic metastasis of liver cancer. Cancer Res. 2002; 62(10):2971-5. View

Mandelker D, Yamashita K, Tokumaru Y, Mimori K, Howard D, Tanaka Y . PGP9.5 promoter methylation is an independent prognostic factor for esophageal squamous cell carcinoma. Cancer Res. 2005; 65(11):4963-8. DOI: 10.1158/0008-5472.CAN-04-3923. View

Tokumaru Y, Yamashita K, Osada M, Nomoto S, Sun D, Xiao Y . Inverse correlation between cyclin A1 hypermethylation and p53 mutation in head and neck cancer identified by reversal of epigenetic silencing. Cancer Res. 2004; 64(17):5982-7. DOI: 10.1158/0008-5472.CAN-04-0993. View

10.

Tezel E, Hibi K, Nagasaka T, Nakao A . PGP9.5 as a prognostic factor in pancreatic cancer. Clin Cancer Res. 2001; 6(12):4764-7. View

11.

Wilkinson K, Lee K, Deshpande S, Duerksen-Hughes P, Boss J, Pohl J . The neuron-specific protein PGP 9.5 is a ubiquitin carboxyl-terminal hydrolase. Science. 1989; 246(4930):670-3. DOI: 10.1126/science.2530630. View

12.

Sato N, Fukushima N, Maitra A, Matsubayashi H, Yeo C, Cameron J . Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res. 2003; 63(13):3735-42. View

13.

Kim M, Lee Y, Moon E, Kim S, Lee J, Kim K . Anti-angiogenic activity of torilin, a sesquiterpene compound isolated from Torilis japonica. Int J Cancer. 2000; 87(2):269-75. View

14.

Herman J, Baylin S . Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003; 349(21):2042-54. DOI: 10.1056/NEJMra023075. View

15.

Hibi K, Trink B, Patturajan M, Westra W, Caballero O, Hill D . AIS is an oncogene amplified in squamous cell carcinoma. Proc Natl Acad Sci U S A. 2000; 97(10):5462-7. PMC: 25851. DOI: 10.1073/pnas.97.10.5462. View

16.

Bittencourt Rosas S, Caballero O, Dong S, da Costa Carvalho M, Sidransky D, Jen J . Methylation status in the promoter region of the human PGP9.5 gene in cancer and normal tissues. Cancer Lett. 2001; 170(1):73-9. DOI: 10.1016/s0304-3835(01)00449-9. View

17.

Liu Y, Fallon L, Lashuel H, Liu Z, Lansbury Jr P . The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell. 2002; 111(2):209-18. DOI: 10.1016/s0092-8674(02)01012-7. View

18.

Mayo L, Seo Y, Jackson M, Smith M, Rivera Guzman J, Korgaonkar C . Phosphorylation of human p53 at serine 46 determines promoter selection and whether apoptosis is attenuated or amplified. J Biol Chem. 2005; 280(28):25953-9. DOI: 10.1074/jbc.M503026200. View

19.

Hibi K, Westra W, Borges M, Goodman S, Sidransky D, Jen J . PGP9.5 as a candidate tumor marker for non-small-cell lung cancer. Am J Pathol. 1999; 155(3):711-5. PMC: 1866887. DOI: 10.1016/S0002-9440(10)65169-3. View

20.

Singh B, Reddy P, Goberdhan A, Walsh C, Dao S, Ngai I . p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas. Genes Dev. 2002; 16(8):984-93. PMC: 152354. DOI: 10.1101/gad.973602. View